Strattera Dosage: Starting Dose, Titration, and Schedule

Strattera (atomoxetine) follows a weight-based dosing schedule in children and a fixed-milligram schedule in adults, with most adults starting at 40 mg per day and working up to a target of 80 mg. Unlike stimulant medications for ADHD, Strattera builds its effect gradually over weeks, which means getting the dose right and sticking with it long enough are both critical to seeing results. The dosing picture is also shaped by individual genetics, liver function, and other medications in ways that go well beyond what a standard prescription label communicates.

Standard Starting and Target Doses

For children and adolescents weighing up to about 70 kg (roughly 154 pounds), Strattera dosing is calculated by body weight. The usual starting point is around 0.5 mg per kilogram per day, with a target dose of about 1.2 mg/kg/day. The maximum recommended dose in this group is 1.4 mg/kg/day or 100 mg, whichever is less.

Adults and children over 70 kg follow a different track. The recommended initiation dose is 40 mg per day for at least three days, after which the prescriber typically increases to a target of 80 mg per day. If the response is still not adequate after another two to four weeks at 80 mg, the dose can go up to a maximum of 100 mg per day.¹ This stepped approach matters because jumping straight to a full dose tends to cause more nausea, stomach upset, and other side effects that lead people to quit the medication before it has a chance to work.

The Suboptimal Dosing Problem

One of the most underappreciated issues with Strattera is that a large share of patients never reach the dose where the drug actually works best. A study of over 12,000 adults newly started on atomoxetine found that roughly 37% were being treated at suboptimal doses, averaging only about 43 mg per day. Just 27% were in the recommended dosing range, averaging around 83 mg per day. The overall mean dose across all patients was about 69 mg per day.²

Why does this happen? Sometimes prescribers start the medication and never follow through with the planned dose increase. Sometimes patients experience early side effects at the starting dose and never push through to the target. And sometimes people feel a partial improvement at 40 mg and assume that is the best the drug can do. The evidence suggests that reaching an adequate dose for a sufficient duration is important for meaningful symptom improvement.³ If you have been on Strattera for a few weeks and feel like it is not helping much, the first question to ask your prescriber is whether you have actually reached the target dose.

How Long Before It Actually Works

Strattera is not like a stimulant that you can feel working within an hour of taking it. Its effect builds over time, which is both its biggest disadvantage and something that catches a lot of people off guard. A pooled analysis of two large adult trials showed statistically significant symptom reduction as early as one week after starting treatment, but the effect size at that point was small. By four weeks, the effect roughly doubled, and it continued growing out to six months, reaching a moderate effect size at 26 weeks.⁴

A clinical review summarizing the trajectory across multiple studies puts the onset of noticeable action at one to two weeks, with incrementally increasing response for up to 24 weeks or even longer.⁵ This means that someone who tries Strattera for three weeks, feels underwhelmed, and stops has probably not given the drug a fair trial. The practical implication is patience: you and your prescriber should plan on at least four to six weeks at the target dose before making a judgment about whether the medication is working. People who stick with it often report that it keeps getting better for months.

Once Daily Versus Twice Daily Dosing

Strattera is commonly prescribed as a single morning dose, but splitting the daily amount into two doses is a legitimate strategy. The reason usually comes down to side effects. In a randomized study of over 200 adults, those who took their full 80 mg dose once daily experienced nausea at about twice the rate of those who split it into two 40 mg doses. The twice-daily group reported nausea in about 16% of cases compared with 32% in the once-daily group. Both approaches worked for ADHD symptoms, though twice-daily dosing showed a slightly greater reduction in symptom scores.⁶

In children, the picture is similar but with a twist. A study comparing once-daily and twice-daily schedules found that splitting the dose reduced stomachaches but was associated with more persistent appetite loss. Adding a second dose also improved parent-rated oppositional symptoms in children who had not responded to once-daily dosing alone, though it did not make a notable difference on teacher-rated ADHD symptoms or classroom functioning.⁷ If nausea or stomach pain is making it hard to tolerate Strattera, asking about a split-dose schedule is a reasonable conversation to have.

Why Genetics Change Everything About Dosing

Strattera is broken down in the body primarily by a liver enzyme called CYP2D6. How much of this enzyme you produce is determined by your genetics, and the variation between people is enormous. Most people are “normal” or “extensive” metabolizers, meaning they clear the drug at a standard rate. But somewhere around 5 to 10% of people of European descent, and a smaller fraction of other populations, are “poor metabolizers” who break down atomoxetine much more slowly.

The practical consequences are striking. In normal metabolizers, atomoxetine’s half-life in the blood is about five hours. In poor metabolizers, it stretches to roughly 22 hours.⁸ A study measuring actual blood levels found that poor metabolizers had nearly 10-fold higher exposure to the drug compared with normal metabolizers, while intermediate metabolizers fell in between at about 1.9-fold higher.⁹ In children specifically, a genotype-stratified study documented a nearly 30-fold range in drug exposure across CYP2D6 groups given the same weight-adjusted dose.¹⁰

What this means in practice: a poor metabolizer taking a “standard” dose is effectively getting the equivalent of a much higher dose. They may experience stronger side effects, including more nausea, faster heart rate, or sleep disruption, at doses that feel perfectly fine for most people. Conversely, an ultra-rapid metabolizer might clear the drug so quickly that standard doses barely register. Some researchers have argued that integrating genetic testing with blood-level monitoring would allow for truly individualized dosing, and a study in Chinese children identified a target peak blood concentration that predicted good response.¹¹ Genetic testing for CYP2D6 status is not yet standard practice everywhere, but it is increasingly available and worth asking about if you are unusually sensitive or unresponsive to Strattera at typical doses.

Drug Interactions That Mimic Genetic Differences

Even if you are a normal metabolizer genetically, certain medications can temporarily turn you into a poor metabolizer by blocking CYP2D6. The most common culprits are SSRI antidepressants, particularly paroxetine (Paxil) and fluoxetine (Prozac), which are potent CYP2D6 inhibitors. A pharmacokinetic study found that taking paroxetine alongside atomoxetine caused a roughly 5.8-fold increase in atomoxetine exposure, while simultaneously reducing levels of the drug’s main metabolite by about 40%.¹²

That 5.8-fold increase is similar in magnitude to what poor metabolizers experience genetically. So if your prescriber adds paroxetine or fluoxetine to your regimen while you are already on Strattera, or vice versa, the Strattera dose may need to come down substantially. Bupropion (Wellbutrin), another common ADHD-adjacent medication, is also a moderate CYP2D6 inhibitor. Quinidine, certain antihistamines, and some antipsychotics can have similar effects. If you are taking Strattera and a new medication is added, it is always worth checking whether the new drug affects CYP2D6.

Liver and Kidney Considerations

Because Strattera is processed heavily by the liver, liver impairment has a direct and sometimes dramatic effect on dosing. The prescribing recommendations are unusually specific here: patients with moderate liver impairment should receive half the normal target dose, and patients with severe liver impairment should receive just one-quarter of the normal dose.¹³ This is a bigger reduction than many prescribers realize, especially for severe impairment. If you have chronic liver disease and are prescribed Strattera at standard doses, it is worth flagging this with your doctor.

Kidney impairment tells a different story. The drug itself is not cleared by the kidneys in significant amounts, but end-stage renal disease can still raise atomoxetine exposure by roughly 65%, likely through changes in protein binding and other indirect mechanisms. A modeling study in patients with end-stage renal disease found that the increased plasma levels translated into proportionally higher drug concentrations in brain tissue as well.¹⁴ For mild to moderate kidney problems, dose adjustment is usually not needed, but severe kidney disease warrants closer monitoring and potentially lower doses.

Blood Pressure and Heart Rate Effects

Strattera can raise heart rate and blood pressure modestly. Across studies of both stimulants and atomoxetine, the average increases are in the range of 3 to 10 beats per minute for heart rate, 3 to 8 mm Hg for systolic blood pressure, and 2 to 14 mm Hg for diastolic blood pressure.¹⁵ For most healthy people, changes in this range are not clinically meaningful. But they can matter if you already have high blood pressure, a rapid resting heart rate, or an underlying heart condition. Baseline and periodic blood pressure and pulse checks are a standard part of monitoring when you are on Strattera, and they become especially important at higher doses or in poor metabolizers who are getting higher-than-expected drug exposure.

How the Drug Moves Through Your Body

After you swallow a Strattera capsule, the drug is absorbed quickly and completely. Blood levels peak within about one to two hours. In children studied specifically for atomoxetine pharmacokinetics, peak levels likewise arrived within one to two hours, and the half-life averaged about three hours at steady state.¹⁶ That short half-life in normal metabolizers explains why the drug seems like it should wear off quickly, yet its clinical effects persist. Atomoxetine works by blocking the norepinephrine transporter in the brain, and the downstream effects of that blockade outlast the drug’s presence in the blood. This is also why it takes weeks to reach full effectiveness: the brain adapts gradually to sustained changes in norepinephrine signaling, not instantly when the drug peaks.

Stopping Strattera

Unlike some psychiatric medications that require slow tapering, Strattera can be stopped abruptly without a withdrawal syndrome. A controlled study specifically designed to look for discontinuation problems compared patients suddenly switched from atomoxetine to placebo against those continuing on placebo. There were no significant differences in adverse events between the groups, and no evidence of symptom rebound or new withdrawal-type symptoms emerging.¹⁷ ADHD symptoms themselves will return once the drug clears the system, of course, but you will not experience the kind of discontinuation effects associated with SSRIs or benzodiazepines. Dose tapering is not considered necessary.

Pregnancy and Breastfeeding

The data on Strattera in pregnancy are thin. A review of pharmacological ADHD treatments during pregnancy and lactation concluded that very little information exists for atomoxetine use during pregnancy, making it difficult to draw firm safety conclusions.¹⁸ Most prescribers treat it cautiously during pregnancy, weighing the individual’s need for ADHD treatment against the uncertain fetal risk.

Breastfeeding is a somewhat different story. A pharmacokinetic analysis of human milk found that atomoxetine transfer into breast milk was minimal, with a relative infant dose of just 0.19%. That is well below the 5% threshold generally considered acceptable for psychoactive medications during breastfeeding.¹⁹ While this is encouraging and suggests low risk, the total body of evidence is still small, so the decision should be made in consultation with a prescriber familiar with your situation.

When Comorbid Conditions Influence the Choice

One reason Strattera sometimes gets chosen over stimulants has less to do with its dosing and more to do with what else is going on. A review of atomoxetine’s effectiveness in people with ADHD plus other conditions found that it was most effective for those who also had anxiety, with effect sizes ranging from moderate to large. It also showed promise for oppositional defiant disorder symptoms. Results were more mixed or limited for people with co-occurring substance use disorders, autism spectrum disorders, depression, bipolar disorder, or Tourette syndrome.²⁰

For children with autism specifically, a systematic review concluded that atomoxetine can be considered a safe off-label option given its relatively favorable side-effect profile.²¹ The anxiety benefit is particularly relevant to dosing conversations because anxiety often coexists with ADHD and can make stimulant side effects harder to tolerate. Strattera at its full recommended dose may address both the inattention and the anxiety in a way that lets patients avoid adding a second medication, which simplifies the regimen and reduces the chance of drug interactions.

Practical Tips for Getting the Dose Right

Given everything above, a few guidelines can help you and your prescriber navigate Strattera dosing more effectively:

Commit to the titration: Do not stay on the starting dose indefinitely. The 40 mg starting dose for adults is intentionally low. If you tolerate it, push up to 80 mg as planned and give it at least four to six weeks before judging whether the drug works.
Try splitting if nausea is a problem: Taking the dose in two halves, morning and late afternoon, can cut nausea rates roughly in half while maintaining or even slightly improving effectiveness.
Take it with food: Although food does not significantly change total absorption, taking Strattera with a meal can reduce the peak spike in blood levels and ease stomach discomfort.
Ask about genetic testing: If standard doses cause unusual side effects or seem to do nothing at all, CYP2D6 testing can reveal whether your metabolism is at one of the extremes. This is a one-time test that can inform not just Strattera dosing but future prescribing decisions for many other drugs.
Audit your other medications: Strong CYP2D6 inhibitors like paroxetine or fluoxetine can dramatically increase Strattera levels. If you start or stop one of these drugs, your Strattera dose may need adjustment.

Strattera dosing is not as simple as picking a number from a chart. The interplay of weight, genetics, liver function, and co-medications means the right dose for one person could be completely wrong for another, even if their ADHD symptoms look identical on paper. The medication rewards patience and careful follow-up, and the most common mistake is giving up before reaching the dose and duration where it has a genuine chance to work.